Skip to main content

Table 3 Number of patients with positive nodes

From: Clinicopathological characteristics and optimal management for esophagogastric junctional cancer; a single center retrospective cohort study

Variable Type E (SQ) (n = 12) Type E (AD) (n = 6) Type Ge (n = 27) Type G (n = 47) P-value
Overall 7/12 (58.3%) 3/6 (50.0%) 19/27 (70.4%) 14/47 (29.8%) 0.003**
Depth of tumor invasion      
 pT1 2/3 (66.7%) 0/3 2/4 (50.0%) 0/23 0.001**
 pT2 1/1 (100%) 2/3 (66.7%) 3/7 (42.9%) 0.497
 pT3 5/9 (55.6%) 2/2 (100.0%) 9/14 (64.3%) 6/10 (60.0%) 0.697
 pT4 6/6 (100%) 5/7 (71.4%) 0.269
Main histological type      
 Squamous-cell carcinoma 7/12 (66.7%) 0/1 0.462
 Adenocarcinoma 3/6 (50.0%) 19/26 (73.1%) 14/47 (29.8%) 0.002**
Location of lymph node†      
 Cervical LN 2/9 (22.2%) 0/2 0.655
 Upper–middle mediastinal 0/11 0/5 0/4
 Lower mediastinal 2/12 (16.7%) 2/6 (33.3%) 2/20 (10.0%) 0/8 0.298
 Perigastric LN 6/12 (50.0%) 3/6 (50.0%) 17/27 (63.0%) 13/47 (27.7%) 0.026*
  Left paracardial 1 2 8 2  
  Right paracardial 3 3 10 5  
  Lesser curvature 4 1 13 10  
  Greater curvature 0 1 4 1  
  Suprapyloric 0 0 0 0  
  Infrapyloric 0 0 1 0  
 LN along left gastric artery 2/12 (16.7%) 1/6 (16.7%) 5/27 (18.5%) 7/47 (14.9%) 0.983
 LN at Celiac trunk 0/6 0/3 1/19 (5.3%) 2/24 (8.3%) 0.837
 LN along hepatic artery 0/3 0/1 3/19 (15.8%) 1/27 (3.7%) 0.459
 LN along splenic artery 0/2 1/3 (33.3%) 2/22 (9.1%) 1/23 (4.3%) 0.356
 LN at splenic hilum 3/17 (17.6%) 0/9 0.262
  1. * P < 0.05; ** P < 0.01.
  2. Number of the patients with nodal metastasis/number of the patients underwet lymph node dissection (%).
  3. ‡ Lower thoracic paraesophageal, diaphragmatic and posterior mediastinal lymph node.
  4. LN Lymph node.